{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T04:18:51Z","timestamp":1748319531024,"version":"3.41.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,26]]},"DOI":"10.7759\/cureus.84855","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:08:23Z","timestamp":1748304503000},"source":"Crossref","is-referenced-by-count":0,"title":["The Treatment Response and Safety Profile for Mirabegron in Women With Overactive Bladder and Hypertension"],"prefix":"10.7759","author":[{"given":"Jean Ee","family":"Neo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark K","family":"Lui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne W","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill C","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpaa186","article-title":"Association of overactive bladder with hypertension and blood pressure control: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"35","author":"Akbar A","year":"2022","unstructured":"Akbar A, Liu K, Michos ED, et al.. Association of overactive bladder with hypertension and blood pressure control: the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Hypertens. 2022, 35:22-30. 10.1093\/ajh\/hpaa186","journal-title":"Am J Hypertens"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.22505","article-title":"Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability","volume":"33","author":"Chapple CR","year":"2014","unstructured":"Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel MC. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014, 33:17-30. 10.1002\/nau.22505","journal-title":"Neurourol Urodyn"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/luts.12193","article-title":"Prevalence of overactive bladder in China, Taiwan, and South Korea: results from a cross-sectional, population-based study","volume":"11","author":"Chuang YC","year":"2019","unstructured":"Chuang YC, Liu SP, Lee KS, et al.. Prevalence of overactive bladder in China, Taiwan, and South Korea: results from a cross-sectional, population-based study. Low Urin Tract Symptoms. 2019, 11:48-55. 10.1111\/luts.12193","journal-title":"Low Urin Tract Symptoms"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-013-0413-z","article-title":"Home blood pressure monitoring is a better predictor of cardiovascular disease and target organ damage than office blood pressure: a systematic review and meta-analysis","volume":"15","author":"Fuchs SC","year":"2013","unstructured":"Fuchs SC, Mello RG, Fuchs FC. Home blood pressure monitoring is a better predictor of cardiovascular disease and target organ damage than office blood pressure: a systematic review and meta-analysis. Curr Cardiol Rep. 2013, 15:413. 10.1007\/s11886-013-0413-z","journal-title":"Curr Cardiol Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S242065","article-title":"Evaluating the effectiveness of an additional risk minimization measure to reduce the risk of prescribing mirabegron to patients with severe uncontrolled hypertension in four European countries","volume":"12","author":"Heintjes EM","year":"2020","unstructured":"Heintjes EM, Bezemer ID, Prieto-Alhambra D, et al.. Evaluating the effectiveness of an additional risk minimization measure to reduce the risk of prescribing mirabegron to patients with severe uncontrolled hypertension in four European countries. Clin Epidemiol. 2020, 12:423-33. 10.2147\/CLEP.S242065","journal-title":"Clin Epidemiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19042286","article-title":"Exploring the relationship between frailty, functional status, polypharmacy, and quality of life in elderly and middle-aged patients with cardiovascular diseases: a one-year follow-up study","volume":"19","author":"Hiriscau EI","year":"2022","unstructured":"Hiriscau EI, Buzdugan EC, Hui LA, Bodolea C. Exploring the relationship between frailty, functional status, polypharmacy, and quality of life in elderly and middle-aged patients with cardiovascular diseases: a one-year follow-up study. Int J Environ Res Public Health. 2022, 19:8-9. 10.3390\/ijerph19042286","journal-title":"Int J Environ Res Public Health"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2010.09993.x","article-title":"Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction","volume":"108","author":"Irwin DE","year":"2011","unstructured":"Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011, 108:1132-8. 10.1111\/j.1464-410X.2010.09993.x","journal-title":"BJU Int"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin DE","year":"2006","unstructured":"Irwin DE, Milsom I, Hunskaar S, et al.. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006, 50:1306-14. 10.1016\/j.eururo.2006.09.019","journal-title":"Eur Urol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58060825","article-title":"Impact of mirabegron administration on the blood pressure and pulse rate in patients with overactive bladder","volume":"58","author":"Ito H","year":"2022","unstructured":"Ito H, Matsuo T, Mitsunari K, Ohba K, Miyata Y. Impact of mirabegron administration on the blood pressure and pulse rate in patients with overactive bladder. Medicina (Kaunas). 2022, 58:5-7. 10.3390\/medicina58060825","journal-title":"Medicina (Kaunas)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00792-9","article-title":"Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta-analysis","volume":"37","author":"Lozano-Ortega G","year":"2020","unstructured":"Lozano-Ortega G, Walker DR, Johnston K, et al.. Comparative safety and efficacy of treatments for overactive bladder among older adults: a network meta-analysis. Drugs Aging. 2020, 37:801-16. 10.1007\/s40266-020-00792-9","journal-title":"Drugs Aging"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S174402","article-title":"Mirabegron in the treatment of overactive bladder: safety and efficacy in the very elderly patient","volume":"15","author":"Makhani A","year":"2020","unstructured":"Makhani A, Thake M, Gibson W. Mirabegron in the treatment of overactive bladder: safety and efficacy in the very elderly patient. Clin Interv Aging. 2020, 15:575-81. 10.2147\/CIA.S174402","journal-title":"Clin Interv Aging"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2023.04.001","article-title":"Predicting mirabegron treatment response in patients with overactive bladder: a post hoc analysis of data from clinical trials","volume":"9","author":"Matta R","year":"2023","unstructured":"Matta R, Saskin R, Neu S, Locke JA, Kowalczyk A, Steup A, Herschorn S. Predicting mirabegron treatment response in patients with overactive bladder: a post hoc analysis of data from clinical trials. Eur Urol Focus. 2023, 9:957-65. 10.1016\/j.euf.2023.04.001","journal-title":"Eur Urol Focus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afu185","article-title":"Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study","volume":"44","author":"Myint PK","year":"2015","unstructured":"Myint PK, Fox C, Kwok CS, Luben RN, Wareham NJ, Khaw KT. Total anticholinergic burden and risk of mortality and cardiovascular disease over 10 years in 21,636 middle-aged and older men and women of EPIC-Norfolk prospective population study. Age Ageing. 2015, 44:219-25. 10.1093\/ageing\/afu185","journal-title":"Age Ageing"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/IJWH.S372597","article-title":"Mirabegron in the management of overactive bladder syndrome","volume":"14","author":"O'Kane M","year":"2022","unstructured":"O'Kane M, Robinson D, Cardozo L, Wagg A, Abrams P. Mirabegron in the management of overactive bladder syndrome. Int J Womens Health. 2022, 14:1337-50. 10.2147\/IJWH.S372597","journal-title":"Int J Womens Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14700","article-title":"Efficacy of mirabegron, a \u03b2(3)-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies","volume":"29","author":"Takahashi S","year":"2022","unstructured":"Takahashi S, Mishima Y, Kuroishi K, Ukai M. Efficacy of mirabegron, a \u03b2(3)-adrenoreceptor agonist, in Japanese women with overactive bladder and either urgency urinary incontinence or mixed urinary incontinence: post-hoc analysis of pooled data from two randomized, placebo-controlled, double-blind studies. Int J Urol. 2022, 29:7-15. 10.1111\/iju.14700","journal-title":"Int J Urol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/2042098616659412","article-title":"Mirabegron in overactive bladder patients: efficacy review and update on drug safety","volume":"7","author":"Warren K","year":"2016","unstructured":"Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016, 7:204-16. 10.1177\/2042098616659412","journal-title":"Ther Adv Drug Saf"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327429-the-treatment-response-and-safety-profile-for-mirabegron-in-women-with-overactive-bladder-and-hypertension","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:08:23Z","timestamp":1748304503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327429-the-treatment-response-and-safety-profile-for-mirabegron-in-women-with-overactive-bladder-and-hypertension"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,26]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.84855","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,26]]}}}